{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:34:40Z","timestamp":1780331680754,"version":"3.54.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Non-compliance to recombinant human growth hormone (rhGH) treatment is universally recognized as a key detrimental factor to achieve the expected clinical outcomes in adult GH deficiency (aGHD). The Easypod\u2122 electronic device allows objective measurement of adherence. Adherence to treatment has been reported to be related with IGF-1 levels and consequently with clinical satisfactory results. The aim of this multicentric, observational, retrospective, 24- month study, is to objectively assess aGHD patients\u2019 compliance to rhGH, using the Easypod\u2122 device. Additionally, the study aims to compare the biochemical responses of adherent vs non-adherent patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty-three patients (28 females and 15 males) affected by aGHD and equipped with Easypod\u2122 from 3 Italian centers were included in the study. Adherence to treatment was defined as the proportion of injections correctly administered during the observational period, out of the expected total number of injections. All patients were evaluated for IGF-1, glucose, insulin, HOMA and QUICKI index, total\/LDL\/HDL cholesterol and triglycerides.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean adherence rate was consistently under 85% across the 2-year observation period (73% at year 2). A trend toward significant difference in adherence was shown when comparing female and male patients (respectively 76% and 61%) after a 2-year period. Among the anamnestic features, the prescribed frequency of administration of rhGH and the number of administered therapies appeared to be the most relevant adherence-influencing factors. A strong direct correlation between IGF-1 z-score and adherence to rhGH therapy was detected in the whole population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Compliance to rhGH therapy is still a major issue in aGHD treatment. Adherence relates to therapy efficacy in aGHD. The use of Easypod\u2122 could be beneficial for physicians to better manage aGHD patients and to achieve improved better biochemical and clinical responses.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1298775","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T04:29:00Z","timestamp":1699849740000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The adult growth hormone multicentric retrospective observational study: a 24-month Italian experience of adherence monitoring via Easypod\u2122 of recombinant growth hormone treatment in adult GH deficiency"],"prefix":"10.3389","volume":"14","author":[{"given":"Antonio","family":"Mancini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Vergani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Giavoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Spaziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Arosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2227","article-title":"Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12477","article-title":"Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: A systematic review of studies on morbidity","volume":"81","author":"Van Bunderen","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2019-0405","article-title":"American Association of Clinical endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care","volume":"25","author":"Yuen","year":"2019","journal-title":"Endocr Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4274\/JCRPE.GALENOS.2019.2019.0153","article-title":"Managing paediatric growth disorders: integrating technology into a personalised approach","volume":"12","author":"Child","year":"2020","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S271453","article-title":"Adherence to r-hGH Therapy in Pediatric Growth Hormone Deficiency: Current Perspectives on How Patient-Generated Data Will Transform r-hGH Treatment Towards Integrated Care","volume":"16","author":"Savage","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00416","article-title":"Relevance of adherence monitoring in adult patients with growth hormone deficiency under replacement therapy: Preliminary monocentric data with EasypoDTM connect","volume":"10","author":"Mancini","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4158\/EP.14.2.143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","author":"Rosenfeld","year":"2008","journal-title":"Endocr Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000350251","article-title":"Understanding the growth hormone therapy adherence paradigm: a systematic review","volume":"79","author":"Fisher","year":"2013","journal-title":"Horm Res Paediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(96)00268-5","article-title":"The assessment of refill compliance using pharmacy records: Methods, validity, and applications","volume":"50","author":"Steiner","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016223","article-title":"Non-compliance with growth hormone treatment in children is common and impairs linear growth","volume":"6","author":"Cutfield","year":"2011","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3233\/SHTI210314","article-title":"Digital health in the management of pediatric growth hormone therapy - 10 years of developments","volume":"281","author":"Koledova","year":"2021","journal-title":"Stud Health Technol Inform"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2021.637209","article-title":"Usefulness and potential pitfalls of long-acting growth hormone analogs","volume":"12","author":"Yuen","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12911-020-01183-1\/FIGURES\/3","article-title":"Analysis of real-world data on growth hormone therapy adherence using a connected injection device","volume":"20","author":"Koledova","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/S40618-019-01046-1","article-title":"Adherence to growth hormone (GH) therapy in na\u00efve to treatment GH-deficient children: data of the Italian Cohort from the Easypod Connect Observational Study (ECOS)","volume":"42","author":"Centonze","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/J.GHIR.2020.101336","article-title":"Adherence and long-term outcomes of therapy in paediatric patients in Greece using the easypodTM electromechanical device for growth hormone treatment: The phase IV multicentre easypodTM connect observational study (ECOS)","author":"Charmandari","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0325","article-title":"Adherence and long-term outcomes of growth hormone therapy with easypodTM in pediatric subjects: Spanish ECOS study","volume":"8","author":"Arnao","year":"2019","journal-title":"Endocr Connect"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0172","article-title":"Adherence and long-term growth: the easypodTM connect observational study (ECOS) in children with growth disorders","volume":"7","author":"Koledova","year":"2018","journal-title":"Endocr Connect"},{"key":"B19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/S12911-021-01491-0","article-title":"Connected health for growth hormone treatment research and clinical practice: learnings from different sources of real-world evidence (RWE)-large electronically collected datasets, surveillance studies and individual patients\u2019 cases","volume":"21","author":"Boman","year":"2021","journal-title":"BMC Med Inform Decis Mak"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2196\/32626","article-title":"Adherence to growth hormone treatment using a connected device in Latin America: real-world exploratory descriptive analysis study","volume":"10","author":"Assefi","year":"2022","journal-title":"JMIR mHealth uHealth"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2174\/1871530320666200929141847","article-title":"\u201cNon-classical\u201d indication for provocative testing of growth hormone: a retrospective cohort study in adult patients under replacement therapy","volume":"21","author":"Mancini","year":"2020","journal-title":"Endocrine Metab Immune Disord - Drug Targets"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans","volume":"85","author":"Katz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S42602","article-title":"The NordiNet\u00ae International Outcome Study and NovoNet\u00ae ANSWER Program\u00ae: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin\u00ae)","volume":"5","author":"H\u00f6ybye","year":"2013","journal-title":"Clin Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/J.GHIR.2019.09.002","article-title":"Growth hormone replacement in adults: Real-world data from two large studies in US and Europe","volume":"50","author":"Weber","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"B26","unstructured":"Adherence to long-term therapies : evidence for action"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/FMEDT.2021.609878","article-title":"Positive impact of targeted educational intervention in children with low adherence to growth hormone treatment identified by use of the easypodTM electronic auto-injector device","volume":"3","author":"Assefi","year":"2021","journal-title":"Front Med Technol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2022.882192\/BIBTEX","article-title":"Integrated digital health solutions in the management of growth disorders in pediatric patients receiving growth hormone therapy: A retrospective analysis","volume":"13","author":"Tornincasa","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4321\/S1886-36552012000400005","article-title":"Women and men report different behaviours in, and reasons formedication non-adherence: a nationwide Swedish survey","volume":"10","author":"Thunander Sundbom","year":"2012","journal-title":"Pharm Pract (Granada)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5001\/OMJ.2011.38","article-title":"Patient medication adherence: measures in daily practice","volume":"26","author":"Jimmy","year":"2011","journal-title":"Oman Med J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1345\/APH.10295","article-title":"Medication adherence in elderly patients receiving home health services following hospital discharge","volume":"35","author":"Gray","year":"2001","journal-title":"Ann Pharmacother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012419.PUB2","article-title":"Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications","volume":"5","author":"Cross","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12875-019-1019-3\/TABLES\/4","article-title":"Adherence to treatment and related factors among patients with chronic conditions in primary care: A cross-sectional study","volume":"20","author":"Fernandez-Lazaro","year":"2019","journal-title":"BMC Fam Pract"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015866415552","article-title":"Intentional and unintentional nonadherence: a study of decision making","volume":"25","author":"Wroe","year":"2002","journal-title":"J Behav Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2023.106805","article-title":"Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis","volume":"193","author":"Mameli","year":"2023","journal-title":"Pharmacol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGAB928","article-title":"Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3","volume":"107","author":"S\u00e4vendahl","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/S11102-020-01046-Y","article-title":"Motivation for and adherence to growth hormone replacement therapy in adults with hypopituitarism: the patients\u2019 perspective","volume":"23","author":"Kreitschmann-Andermahr","year":"2020","journal-title":"Pituitary"},{"key":"B38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3390\/ijms19010290","article-title":"Growth hormone (GH) and cardiovascular system","volume":"19","author":"Caicedo","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03292.x","article-title":"The GH-IGF-I axis and the cardiovascular system: Clinical implications","volume":"69","author":"Colao","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0306","article-title":"Growth hormone replacement therapy in adults: 30 years of personal clinical experience","volume":"179","author":"J\u00f8rgensen","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1313","article-title":"Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis","volume":"92","author":"Le Corvoisier","year":"2007","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1298775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T04:29:03Z","timestamp":1699849743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1298775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":41,"alternative-id":["10.3389\/fendo.2023.1298775"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1298775","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"article-number":"1298775"}}